New hope for early MS: Twice-Yearly infusion trial launches
NCT ID NCT07225361
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called Ublituximab (Briumvi) given twice a year to people with early relapsing multiple sclerosis. Researchers want to see if it is safe and how it affects a nerve damage marker in the blood. About 40 adults with mild disability will take part for about one year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Northwestern Memorial Hospital
RECRUITINGChicago, Illinois, 60611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we decode the different types of pain in multiple sclerosis?
- Can a blood pressure pill slow MS disability?
- Hidden MS progression: can brain scans and blood tests predict it?
- Can Brain-Training apps fix sleep in MS?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?